338 related articles for article (PubMed ID: 30955196)
41. Identification of novel serological biomarkers for inflammatory bowel disease using Escherichia coli proteome chip.
Chen CS; Sullivan S; Anderson T; Tan AC; Alex PJ; Brant SR; Cuffari C; Bayless TM; Talor MV; Burek CL; Wang H; Li R; Datta LW; Wu Y; Winslow RL; Zhu H; Li X
Mol Cell Proteomics; 2009 Aug; 8(8):1765-76. PubMed ID: 19357087
[TBL] [Abstract][Full Text] [Related]
42. Impaired coronary microvascular and left ventricular diastolic function in patients with inflammatory bowel disease.
Caliskan Z; Gokturk HS; Caliskan M; Gullu H; Ciftci O; Ozgur GT; Guven A; Selcuk H
Microvasc Res; 2015 Jan; 97():25-30. PubMed ID: 25128749
[TBL] [Abstract][Full Text] [Related]
43. Peripheral cytokine profile in Chilean patients with Crohn's disease and ulcerative colitis.
Beltrán CJ; Candia E; Erranz B; Figueroa C; Gonzalez MJ; Quera R; Hermoso MA
Eur Cytokine Netw; 2009 Mar; 20(1):33-8. PubMed ID: 19318319
[TBL] [Abstract][Full Text] [Related]
44. TNFAIP6 is a potential biomarker of disease activity in inflammatory bowel disease.
Yu Q; Zhang S; Wang H; Zhang Y; Feng T; Chen B; He Y; Zeng Z; Chen M
Biomark Med; 2016 May; 10(5):473-83. PubMed ID: 27088253
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of Ischemia-Modified Albumin in Patients with Inflammatory Bowel Disease.
Guntas G; Sahin A; Duran S; Kahraman R; Duran I; Sonmez C; Calhan T; Sokmen HM
Clin Lab; 2017 Feb; 63(2):341-347. PubMed ID: 28182340
[TBL] [Abstract][Full Text] [Related]
46. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype.
Seow CH; Stempak JM; Xu W; Lan H; Griffiths AM; Greenberg GR; Steinhart AH; Dotan N; Silverberg MS
Am J Gastroenterol; 2009 Jun; 104(6):1426-34. PubMed ID: 19491856
[TBL] [Abstract][Full Text] [Related]
47. Proinflammatory cytokines and IL-10 in inflammatory bowel disease and colorectal cancer patients.
Szkaradkiewicz A; Marciniak R; Chudzicka-Strugała I; Wasilewska A; Drews M; Majewski P; Karpiński T; Zwoździak B
Arch Immunol Ther Exp (Warsz); 2009; 57(4):291-4. PubMed ID: 19578817
[TBL] [Abstract][Full Text] [Related]
48. Fecal proteolytic profiling of pediatric inflammatory bowel disease: A pilot study.
Haak W; Jagt JZ; de Meij TGJ; Bikker FJ; Brand HS; de Boer NKH; Kaman WE
FASEB J; 2024 May; 38(9):e23627. PubMed ID: 38690708
[TBL] [Abstract][Full Text] [Related]
49. Serum ST2 in inflammatory bowel disease: a potential biomarker for disease activity.
Boga S; Alkim H; Koksal AR; Ozagari AA; Bayram M; Tekin Neijmann S; Sen I; Alkim C
J Investig Med; 2016 Jun; 64(5):1016-24. PubMed ID: 27001944
[TBL] [Abstract][Full Text] [Related]
50. [Role of biological markers in inflammatory bowel disease].
Gisbert JP; González-Lama Y; Maté J
Gastroenterol Hepatol; 2007 Mar; 30(3):117-29. PubMed ID: 17374324
[TBL] [Abstract][Full Text] [Related]
51. Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease.
Straub RH; Vogl D; Gross V; Lang B; Schölmerich J; Andus T
Am J Gastroenterol; 1998 Nov; 93(11):2197-202. PubMed ID: 9820396
[TBL] [Abstract][Full Text] [Related]
52. A Panel of Methylated MicroRNA Biomarkers for Identifying High-Risk Patients With Ulcerative Colitis-Associated Colorectal Cancer.
Toiyama Y; Okugawa Y; Tanaka K; Araki T; Uchida K; Hishida A; Uchino M; Ikeuchi H; Hirota S; Kusunoki M; Boland CR; Goel A
Gastroenterology; 2017 Dec; 153(6):1634-1646.e8. PubMed ID: 28847750
[TBL] [Abstract][Full Text] [Related]
53. Diagnostic value of the serum platelet-activating factor acetylhydrolase activity in inflammatory bowel disease.
Oshimoto H; Okamura S; Iida T; Ishikawa T; Hosaka K; Mori M
Tohoku J Exp Med; 2005 Sep; 207(1):65-71. PubMed ID: 16082157
[TBL] [Abstract][Full Text] [Related]
54. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
[TBL] [Abstract][Full Text] [Related]
55. Amino acids-targeted metabolomics reveals novel diagnostic biomarkers for ulcerative colitis and Crohn's disease.
Zhou G; Liu H; Wei P; He Q; Zhang J; Shi Q; Liu T; Liu S
Amino Acids; 2023 Mar; 55(3):349-358. PubMed ID: 36625991
[TBL] [Abstract][Full Text] [Related]
56. Association between red cell distribution width and disease activity in patients with inflammatory bowel disease.
Song CS; Park DI; Yoon MY; Seok HS; Park JH; Kim HJ; Cho YK; Sohn CI; Jeon WK; Kim BI
Dig Dis Sci; 2012 Apr; 57(4):1033-8. PubMed ID: 22147246
[TBL] [Abstract][Full Text] [Related]
57. Oversecretion and Overexpression of Nicotinamide Phosphoribosyltransferase/Pre-B Colony-Enhancing Factor/Visfatin in Inflammatory Bowel Disease Reflects the Disease Activity, Severity of Inflammatory Response and Hypoxia.
Neubauer K; Bednarz-Misa I; Walecka-Zacharska E; Wierzbicki J; Agrawal A; Gamian A; Krzystek-Korpacka M
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621173
[TBL] [Abstract][Full Text] [Related]
58. Multigene analysis can discriminate between ulcerative colitis, Crohn's disease, and irritable bowel syndrome.
von Stein P; Lofberg R; Kuznetsov NV; Gielen AW; Persson JO; Sundberg R; Hellstrom K; Eriksson A; Befrits R; Ost A; von Stein OD
Gastroenterology; 2008 Jun; 134(7):1869-81; quiz 2153-4. PubMed ID: 18466904
[TBL] [Abstract][Full Text] [Related]
59. The risk of colorectal cancer in inflammatory bowel disease: a hospital-based cohort study from Korea.
Lee HS; Park SH; Yang SK; Ye BD; Kim JH; Kim SO; Soh JS; Lee S; Bae JH; Lee HJ; Yang DH; Kim KJ; Byeon JS; Myung SJ; Yoon YS; Yu CS; Kim JH
Scand J Gastroenterol; 2015 Feb; 50(2):188-96. PubMed ID: 25515241
[TBL] [Abstract][Full Text] [Related]
60. Diagnostic accuracy of fecal lactoferrin for inflammatory bowel disease: a meta-analysis.
Wang Y; Pei F; Wang X; Sun Z; Hu C; Dou H
Int J Clin Exp Pathol; 2015; 8(10):12319-32. PubMed ID: 26722419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
